The Life Sciences Report Interviews ProMIS CEO, Dr. Elliot Goldstein. Click here or on the image below to view the full interview.
The Life Sciences Report Interviews ProMIS CEO, Dr. Elliot Goldstein
Company News
- ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer’s Disease April 10, 2018
- ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing April 3, 2018
- ProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory Board March 20, 2018
Scientific Presentations
- Hope For Alzheimer’s Disease February 2, 2018
- Eugene Williams, Executive Chairman presents at Noble Capital Markets’ Fourteenth Annual Investor Conference January 31, 2018
- Not All Amyloid-beta Therapeutics Are Created Equal: Promis Neurosciences Lead Product Candidate For Alzheimer’s Disease Shows Improved Therapeutic Potency Versus Other Amyloid Beta-directed Antibodies January 25, 2018